Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/65433
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Ca2+-binding allergens from olive pollen exhibit biochemical and immunological activity when expressed in stable transgenic Arabidopsis

AutorLedesma, Amalia CSIC; Moral, Verónica; Villalba, Mayte; Salinas, Julio CSIC ORCID ; Rodríguez, Rosalía
Palabras claveAllergens
Ole e 3
Ole e 8
olive pollen
plant-expression
Fecha de publicaciónoct-2006
EditorWiley-Blackwell
CitaciónFEBS Journal 273(19):4425-4434(2006)
ResumenEmploying transgenic plants as alternative systems to the conventional Escherichia coli, Pichia pastoris or baculovirus hosts to produce recombinant allergens may offer the possibility of having available edible vaccines in the near future. In this study, two EF-hand-type Ca2+-binding allergens from olive pollen, Ole e 3 and Ole e 8, were produced in transgenic Arabidopsis thaliana plants. The corresponding cDNAs, under the control of the constitutive CaMV 35S promoter, were stably incorporated into the Arabidopsis genome and encoded recombinant proteins, AtOle e 3 and AtOle e 8, which exhibited the molecular properties (i.e. MS analyses and CD spectra) of their olive and/or E. coli counterparts. Calcium-binding assays, which were carried out to assess the biochemical activity of AtOle e 3 and AtOle e 8, gave positive results. In addition, their mobilities on SDS/PAGE were according to the conformational changes derived from their Ca2+-binding capability. The immunological behaviour of Arabidopsis-expressed proteins was equivalent to that of the natural- and/or E. coli-derived allergens, as shown by their ability to bind allergen-specific rabbit IgG antiserum and IgE from sensitized patients. These results indicate that transgenic plants constitute a valid alternative to obtain allergens with structural and immunological integrity not only for scaling up production, but also to develop new kind of vaccines for human utilization
Descripción10 páginas, 6 figuras, 1 tabla -- PAGS nros. 4425-4434
Versión del editorhttps://dx.doi.org/10.1111/j.1742-4658.2006.05417.x
URIhttp://hdl.handle.net/10261/65433
DOI10.1111/j.1742-4658.2006.05417.x
ISSN1742-464X
E-ISSN1742-4658
Aparece en las colecciones: (CIB) Artículos
(INIA) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
restringido.pdf21,67 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

7
checked on 22-abr-2024

WEB OF SCIENCETM
Citations

6
checked on 29-feb-2024

Page view(s)

306
checked on 24-abr-2024

Download(s)

194
checked on 24-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.